PREVIEW: Pfizer Inc (PFE) earnings due 08/Feb at 11:45GMT/06:45EST
Pfizer Inc (PFE) Q4 2021 (USD): EPS (exp. 0.87/0.82 GAAP), Revenue (exp. 24.12bln)
KEY PHARMA SALES:
- BNT162/Comirnaty: (exp. 12.39bln)
- Prevnar: (exp. 1.67bln)
- Ibrance: (exp. 1.42bln)
- Eliquis: (exp. 1.38bln)
- Xeljanz: (exp. 0.64bln)
DIVIDEND:
- FY Dividend: (exp. 1.59)
EPS GUIDANCE:
- Q1 2022 EPS View: (exp. 1.55/1.48 GAAP)
- FY 2022 EPS View: (exp. 6.69/5.92 GAAP)
REVENUE GUIDANCE:
- Q1 2022 Revenue View: (exp. 24.79bln)
- FY 2022 Revenue View: (exp. 105.48bln)
INDEX WEIGHT:
- 0.8% SPX weight
- Sector/Industry: Health Care/Pharmaceuticals
BROKER RATING:
- Avg Rating: 'Buy'
- Avg Price Target: USD 59.68
- Price Target Changes (last 30 days): 5 upward vs 3 downward
07 Feb 2022 - 17:00- Equities- Source: Newswires
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts